Glooko Keeps Diabetes Management Space Hot with M&A

The Palo Alto, CA-based company is adding machine learning to its arsenal with the acquisition of xbird.

Omar Ford

January 31, 2022

2 Min Read
Courtesy of Feodora Chiosea / Alamy Stock Vector

Glooko is dipping into the field of artificial intelligence and machine learning with its latest acquisition. The company, which specializes in digital health solutions for diabetes and chronic illnesses, said it was acquiring xbird for an undisclosed sum.

Xbird is developing Just In Time Adaptive Intervention (JITAI) technologies to support patients and their providers in predicting behavior and managing diabetes. Palo Alto, CA-based Glooko said the acquisition could further broaden its platform offerings.

Specifically, Glooko will integrate the xbird JITAI digital coaching software with its established platform which is used daily by more than 7500 clinics globally and over 1M users. Glooko plans to enable users of their platform globally to utilize these solutions to better manage their diabetes and related chronic conditions.

Sebastian Sujka, CEO and Co-Founder of xbird stated, "xbird and Glooko are a great fit. We share a commitment to providing solutions that address multiple chronic conditions, delivering measurable outcomes, and we have a common mission to broadly serve all patients in need. Our goal is to continue the design of digital health solutions for those living with these conditions and to make our capabilities accessible to as many patients as possible."

Sujka will join Glooko as the Managing Director of Glooko GmbH, along with all of the xbird staff.

This latest acquisition follows several big developments in the medtech section of diabetes treatment. In mid-January Dexcom CEO Kevin Sayer shed light on the company’s 2022 outlook and shared data for its Dexcom G7 continuous glucose monitor – one of the most anticipated technologies in the space. The San Diego, CA-based company has filed for FDA approval for the device.

Senseonics, Dexcom’s chief CGM competitor, is waiting for approval for the next generation of the Eversense 180-day CGM. The Germantown, MD-based company said a decision from FDA is now expected in the coming weeks.

The company submitted the PMA supplement for Eversense in October 2020 but a backlog has delayed potential approval timing for the device.


About the Author(s)

Omar Ford

Omar Ford is MD+DI's Editor-in-Chief. You can reach him at [email protected].


Sign up for the QMED & MD+DI Daily newsletter.

You May Also Like